Comparison of a fixed-dose combination of Celecoxib/PG201 [Layla®] versus co-administration of individual formulations in healthy participants: A randomized trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
    • Subject Terms:
      Celecoxib*/administration & dosage ; Celecoxib*/pharmacokinetics ; Celecoxib*/adverse effects ; Cross-Over Studies* ; Cyclooxygenase 2 Inhibitors*/administration & dosage ; Cyclooxygenase 2 Inhibitors*/pharmacokinetics ; Cyclooxygenase 2 Inhibitors*/adverse effects ; Drug Combinations* ; Healthy Volunteers*; Humans ; Male ; Adult ; Female ; Young Adult ; Plant Extracts/administration & dosage ; Plant Extracts/pharmacokinetics ; Plant Extracts/adverse effects ; Middle Aged
    • Abstract:
      Background: Osteoarthritis (OA) is a prevalent joint disease affecting the spine, hands, hips, knees, and feet. However, definitive drugs for OA are lacking, and current treatments are limited owing to inconvenient administration, inadequate functional improvement, and long-term side effects including gastrointestinal and cardiovascular adverse events. Therefore, in this study, we aimed to assess the pharmacokinetics and safety profiles of PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor, by comparing its administration as an FDC and the corresponding individual formulations in healthy subjects.
      Patients and Methods: A randomized, open-label, single-dose, 2 × 2 crossover design with a cohort of healthy participants. All subjects received a single FDC tablet (405.4 mg PG201 and 100 mg celecoxib) or the individual formulations, with 7-day washout period between administrations. The estimation of maximum plasma concentration and area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration of celecoxib involved determining the geometric mean ratios and 90% confidence intervals of the FDC compared to its individual formulations.
      Results: Forty-six participants were enrolled; however, only 44 completed the study. The geometric mean ratios (90% confidence intervals) for the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and maximum plasma concentration of celecoxib were 1.1124 (1.0601-1.1672) and 1.2788 (1.1708-1.3969), respectively. The time of maximum plasma concentration range was 1.0 to 4.0 hours and 1.0 to 6.0 hours (minimum-maximum) for the FDC and individual formulations, respectively. Seven adverse events occurred in 6 subjects.
      Conclusion: The systemic exposure and safety profiles of the individual and FDC formulations were similar, supporting their potential as an innovative and effective therapeutic approach for OA treatment. All relevant data are within the paper and its Supporting Information files.
      Competing Interests: HK and H-YM are employees of the PMG Pharm Co., Ltd. All the other authors have no conflicts of interest to disclose.
      (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
    • References:
      Cureus. 2023 Apr 3;15(4):e37080. (PMID: 37153279)
      Curr Opin Drug Discov Devel. 2010 Jan;13(1):50-65. (PMID: 20047146)
      Semin Arthritis Rheum. 2016 Dec;46(3):259-260. (PMID: 27519477)
      Pain Ther. 2021 Dec;10(2):783-808. (PMID: 33876393)
      Clin Pharmacol Ther. 2020 Mar;107(3):650-661. (PMID: 31608434)
      MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1101-1107. (PMID: 37824422)
      Biorheology. 2002;39(1-2):237-46. (PMID: 12082286)
      Osteoarthritis Cartilage. 2019 Feb;27(2):230-239. (PMID: 30391394)
      Phytother Res. 2009 Nov;23(11):1497-515. (PMID: 19856319)
      J Ethnopharmacol. 2016 Apr 2;181:1-7. (PMID: 26821189)
      Cochrane Database Syst Rev. 2014 May 22;(5):CD002947. (PMID: 24848732)
      Osteoarthritis Cartilage. 2018 Oct;26(10):1263-1273. (PMID: 29890262)
      Biomed Res Int. 2015;2015:595273. (PMID: 26000299)
      Nagoya J Med Sci. 2015 Feb;77(1-2):81-93. (PMID: 25797973)
      Rheumatol Int. 2014 Oct;34(10):1369-78. (PMID: 24531687)
      J Rheum Dis. 2024 Apr 1;31(2):68-78. (PMID: 38559799)
      Arch Pharm Res. 2016 Feb;39(2):231-239. (PMID: 26306655)
      Int J Mol Sci. 2021 Feb 09;22(4):. (PMID: 33572320)
    • Molecular Sequence:
      ClinicalTrials.gov NCT03876210
    • Accession Number:
      JCX84Q7J1L (Celecoxib)
      0 (Cyclooxygenase 2 Inhibitors)
      0 (Drug Combinations)
      0 (Plant Extracts)
    • Publication Date:
      Date Created: 20241119 Date Completed: 20241119 Latest Revision: 20241227
    • Publication Date:
      20241228
    • Accession Number:
      PMC11575945
    • Accession Number:
      10.1097/MD.0000000000040494
    • Accession Number:
      39560548